Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Piotroski F-Score: 4 (As of Jul. 12, 2026) — 33% Below Median


TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
58 GF Score
Price NT$38.15
GF Value NT$37.92
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co Piotroski F-Score?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 58 Piotroski F-Score is 4 as of Jul. 12, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates TPE:1762 with a GF Score™ of 58/100 and a GF Value™ of NT$37.92 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,333 Biotechnology companies, Chunghwa Chemical Synthesis & Biotech Co ranks better than 73.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chunghwa Chemical Synthesis & Biotech Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score or its related term are showing as below:

TPE:1762' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Chunghwa Chemical Synthesis & Biotech Co was 7. The lowest was 2. And the median was 6.

Chunghwa Chemical Synthesis & Biotech Co  (TPE:1762) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chunghwa Chemical Synthesis & Biotech Co Piotroski F-Score Related Terms


Chunghwa Chemical Synthesis & Biotech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co Piotroski F-Score Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 2.00 6.00 4.00

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 5.00 5.00 4.00

TPE:1762 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chunghwa Chemical Synthesis & Biotech Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score falls into.


TPE:1762
58GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 7.318 + -67.332 + -42.579 + -141.254 = NT$-243.8 Mil.
Cash Flow from Operations was 76.143 + -25.564 + 112.625 + -20.593 = NT$142.6 Mil.
Revenue was 192.952 + 344.039 + 154.47 + 113.417 = NT$804.9 Mil.
Gross Profit was 60.531 + 29.22 + -9.223 + -89.392 = NT$-8.9 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(4762.738 + 4745.113 + 4592.662 + 4438.664 + 4317.353) / 5 = NT$4571.306 Mil.
Total Assets at the begining of this year (Dec24) was NT$4,762.7 Mil.
Long-Term Debt & Capital Lease Obligation was NT$602.8 Mil.
Total Current Assets was NT$1,058.9 Mil.
Total Current Liabilities was NT$356.7 Mil.
Net Income was 40.555 + 21.077 + -8.239 + -0.361 = NT$53.0 Mil.

Revenue was 251.712 + 461.158 + 348.18 + 286.325 = NT$1,347.4 Mil.
Gross Profit was 117.296 + 117.701 + 87.878 + 71.443 = NT$394.3 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(5171.651 + 5225.702 + 4994.468 + 4866.909 + 4762.738) / 5 = NT$5004.2936 Mil.
Total Assets at the begining of last year (Dec23) was NT$5,171.7 Mil.
Long-Term Debt & Capital Lease Obligation was NT$704.0 Mil.
Total Current Assets was NT$1,441.2 Mil.
Total Current Liabilities was NT$425.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chunghwa Chemical Synthesis & Biotech Co's current Net Income (TTM) was -243.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chunghwa Chemical Synthesis & Biotech Co's current Cash Flow from Operations (TTM) was 142.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-243.847/4762.738
=-0.05119891

ROA (Last Year)=Net Income/Total Assets (Dec23)
=53.032/5171.651
=0.01025437

Chunghwa Chemical Synthesis & Biotech Co's return on assets of this year was -0.05119891. Chunghwa Chemical Synthesis & Biotech Co's return on assets of last year was 0.01025437. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chunghwa Chemical Synthesis & Biotech Co's current Net Income (TTM) was -243.8. Chunghwa Chemical Synthesis & Biotech Co's current Cash Flow from Operations (TTM) was 142.6. ==> 142.6 > -243.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=602.789/4571.306
=0.13186363

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=703.979/5004.2936
=0.140675

Chunghwa Chemical Synthesis & Biotech Co's gearing of this year was 0.13186363. Chunghwa Chemical Synthesis & Biotech Co's gearing of last year was 0.140675. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1058.883/356.706
=2.96850347

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=1441.225/425.288
=3.38882122

Chunghwa Chemical Synthesis & Biotech Co's current ratio of this year was 2.96850347. Chunghwa Chemical Synthesis & Biotech Co's current ratio of last year was 3.38882122. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chunghwa Chemical Synthesis & Biotech Co's number of shares in issue this year was 55.34. Chunghwa Chemical Synthesis & Biotech Co's number of shares in issue last year was 77.56. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-8.864/804.878
=-0.01101285

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=394.318/1347.375
=0.29265646

Chunghwa Chemical Synthesis & Biotech Co's gross margin of this year was -0.01101285. Chunghwa Chemical Synthesis & Biotech Co's gross margin of last year was 0.29265646. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=804.878/4762.738
=0.16899481

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1347.375/5171.651
=0.26053092

Chunghwa Chemical Synthesis & Biotech Co's asset turnover of this year was 0.16899481. Chunghwa Chemical Synthesis & Biotech Co's asset turnover of last year was 0.26053092. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chunghwa Chemical Synthesis & Biotech Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Piotroski F-Score of 4 as of Jul. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #347 out of 1333 companies in the Biotechnology industry, placing it in the top 26%.
Is Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score too high?
Chunghwa Chemical Synthesis & Biotech Co's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Chunghwa Chemical Synthesis & Biotech Co's value of 4 is 33.3% above this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #347 out of 1333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #347 out of 1333 companies for Piotroski F-Score. This puts Chunghwa Chemical Synthesis & Biotech Co in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Chunghwa Chemical Synthesis & Biotech Co's value of 4 is 33.3% above this benchmark. Historically, Chunghwa Chemical Synthesis & Biotech Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Chunghwa Chemical Synthesis & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.92, compared to a current price of NT$38.15 — trading 0.6% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 33.3% above the Biotechnology industry median of 3.00. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Piotroski F-Score is 4 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be overvalued. The current stock price of NT$38.15 is trading 0.6% above its estimated GF Value™ of NT$37.92. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1762:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: NT$37.92 vs. price of NT$38.15 (0.6% above fair value)
  • GF Score™: 58/100 with 8 warning signs
  • Industry Position: 33.3% above the Biotechnology median (#347 of 1333)

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
58GF Score

Get the complete analysis for TPE:1762

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.15
Price
NT$37.92
GF Value